Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease

Robert A. HauserDepartments of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, USACorrespondence[email protected]

Heinz ReichmannDepartment of Neurology, University of Technology, Dresden, Germany

Mark LewDepartment of Neurology, Keck/USC School of Medicine, Los Angeles, California, USA

Afsaneh AsgharianGlaxoSmithKline, Research Triangle Park, North Carolina, USA

Clare MakumiGlaxoSmithKline, Research Triangle Park, North Carolina, USA

Kenneth J. ShulmanGlaxoSmithKline, Research Triangle Park, North Carolina, USA

REFERENCES

Grosset, K. A., Reid, J. L., & Grosset, D. G. (2005). Medicine-taking behavior: Implications of suboptimal compliance in Parkinson's disease. Movement Disorders, 20, 1397–404.
PubMed Web of Science ®Google Scholar
Holloway, R. G., Shoulson, I., Fahn, S., Kieburtz, K., Lang, A., Marek, K. (2004). Pramipexole vs levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Archives of Neurology, 61, 1044–1053.
PubMed Web of Science ®Google Scholar
Pahwa, R., Stacy, M. A., Factor, S. A. (2007). Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. Neurology, 68, 1108–1115.
PubMed Web of Science ®Google Scholar
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. New England Journal of Medicine, 342, 1484–1491.
PubMed Web of Science ®Google Scholar
Stocchi, F., Hersh, B. P., Scott, B. L., Nausieda, P. A., Giorgi L, & the Ease-PD Monotherapy Study Investigators. (2008). Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: A randomized, double-blind, non-inferiority crossover study. Current Medical Research and Opinion, 24(10), 2883–2895.
PubMed Web of Science ®Google Scholar
Tompson, D., & Vearer, D. (2007). Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: Results of two randomized studies in patients with Parkinson's disease. Clinical Therapeutics, 29, 2654–2666.
PubMed Web of Science ®Google Scholar
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C. (2003). Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology, 54, 93–101.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease

REFERENCES

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease

REFERENCES

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date